Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
A retrospective cohort analysis found that patients with DLBCL who experienced infusion reactions during treatment with rituximab had prolonged overall survival. In addition, progression-free survival was affected in subsets of patients with DLBCL.
Anti-CD19 chimeric antigen receptor T cells made from umbilical cord blood cells had a distinct phenotype and may offer off-the-shelf potential.
Dose and frequency of vaccination, sex, Ann Arbor stage, ibrutinib impact immunity effects of vaccine
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
Pembrolizumab showed clinical benefit in patients with relapsed or refractory primary mediastinal large B-cell lymphoma, according to KEYNOTE-013 and KEYNOTE-170.
A retrospective cohort study explored outcomes for pregnant women with HL who received antenatal chemotherapy compared with a match cohort of nonpregnant women.
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Assay could help clarify pathogenesis of breast-implant related lymphomas.
Study sought to determine if response to upfront treatment in children and adolescents with Hodgkin lymphoma is influenced by race/ethnicity.
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
For patients with non-Hodgkin lymphoma, switching from intravenous to subcutaneous rituximab appeared to be effective and presented no new safety issues.
Infections occurred in 33 of 54 patients for whom data were available, and 80% of infections were treated in an outpatient setting.
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
In this study, patients were classified as either PET-negative or PET-positive using the 5-point Deauville criteria.
Patients with follicular lymphoma who had disease progression within 24 months of diagnosis were found to have lower intratumoral immune infiltration.
Researchers determined that several validated assessment tools are needed to measure health-related quality of life in patients with cutaneous T-cell lymphoma.